Rouette J, et al. - Among people with type 2 diabetes, experts aspired to explore if dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists were correlated with an increased lung cancer risk. They identified 130,340 people newly treated with antidiabetes drugs between January 2007 and March 2017, with follow-up until March 2018. In total, 790 people were newly diagnosed with lung cancer (median follow-up 4.6 years, incidence rate 1.5/1000 person-years, 95% CI 1.4–1.6). According to this population-based cohort study, the use of incretin-based drugs was not linked to increased lung cancer risk in people with type 2 diabetes.